Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences (NASDAQ: CAI) announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026.

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. Shares will keep trading on NASDAQ and also list on NYSE Texas under the CAI ticker, aiming for greater investor exposure, especially in Texas.

Positive

• Dual listing on NYSE Texas effective June 17, 2026
• Maintains NASDAQ primary listing while expanding investor access under ticker CAI

Negative

• None.

Argus Jun 16 session

-1.10% close to close Open Argus

Details

News Market Reaction – CAI

On Jun 16, the day this news came out, CAI closed 1.10% below the previous close.

Data tracked by StockTitan Argus for the Jun 16 session.

Key Figures

Texas employees: over 450 employees Dual listing effective date: June 17, 2026

Texas employees

over 450 employees

Caris headcount in Texas mentioned with headquarters

Dual listing effective date

June 17, 2026

Effective date for NYSE Texas dual listing

Historical Context

5 past events · Latest: Jun 08

5 events

1. Jun 08

   Share repurchase plan

   24h Move

   +1.6%

   Board authorized up to $100M in common stock repurchases.

2. May 26

   Branding/patient campaign

   24h Move

   -0.2%

   Launch of "Behind the Diagnosis" campaign highlighting GPSai impact.

3. May 15

   Clinical value study

   24h Move

   -4.6%

   Study on Caris Lookback Program showing new therapy eligibility findings.

4. May 11

   WES TMB outcomes study

   24h Move

   -1.3%

   Data showing WES-based TMB better predicts pembrolizumab benefit.

5. May 08

   Regulatory application

   24h Move

   -1.3%

   Application for Caris Assure blood-based profiling authorization in New York.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

whole genome sequencing, artificial intelligence, machine learning, molecular profiling, +2 more

6 terms

whole genome sequencing medical

"leveraging Whole Genome, Whole Exome Sequencing and Whole Transcriptome Sequencing"

Whole genome sequencing is a laboratory method that reads an individual’s complete DNA instruction book, capturing all genetic letters rather than just selected parts. For investors, it matters because it can reveal new ways to diagnose, prevent or treat disease and to develop tests or drugs — like upgrading from a map of a few streets to a full city blueprint — which can create commercial opportunities, influence regulatory pathways and change healthcare costs and demand.

artificial intelligence technical

"enabled by the cloud and artificial intelligence/machine learning."

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

machine learning technical

"enabled by the cloud and artificial intelligence/machine learning."

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

molecular profiling medical

"continues to develop and commercialize advanced molecular profiling solutions"

Molecular profiling is a laboratory analysis that reads a patient’s disease at the level of genes, proteins or other molecules to reveal its specific characteristics—think of it as reading the instruction manual for a tumor or condition. For investors, it matters because the results guide which targeted treatments, diagnostics or tests will be used, shaping clinical demand, regulatory approval paths and potential revenue for companies developing precision medicines and companion tests.

precision medicine medical

"next-generation AI TechBio company and precision medicine pioneer actively developing"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

clinico-genomic medical

"multimodal clinico-genomic database and computing capability needed to analyze"

Clinico-genomic describes the combination of clinical patient information (symptoms, treatment outcomes, medical history) with genomic data (DNA changes and tumor genetics) to gain a fuller picture of disease and treatment response. For investors, this integrated approach can reveal which drugs are likely to work, identify new drug targets, and de-risk development programs — like fitting medical and genetic puzzle pieces together to predict which therapies will succeed in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets.

Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.

"Establishing a dual listing on NYSE Texas reflects both our continued growth as a public company and our deep roots in Texas, including our headquarters and over 450 Caris employees in the state," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. "This milestone underscores our commitment to innovation, our heritage in Texas and our mission to improve the lives of patients through precision medicine."

"We are proud to welcome Caris Life Sciences to NYSE Texas," said Lynn Martin, President, NYSE Group. "With deep roots in the state and a world-class platform at the forefront of AI and precision medicine, Caris is exactly the kind of innovative company that NYSE Texas was designed to celebrate and support."

Headquartered in Irving, Texas, Caris continues to develop and commercialize advanced molecular profiling solutions leveraging Whole Genome, Whole Exome Sequencing and Whole Transcriptome Sequencing, enabled by the cloud and artificial intelligence/machine learning. These capabilities support improved diagnosis, therapy selection, disease monitoring and drug development.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.  

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.  

Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

Investor Relations:
IR@CarisLS.com
917.689.3511

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-dual-listing-on-nyse-texas-302801211.html

SOURCE Caris Life Sciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dual listing did Caris Life Sciences (NASDAQ: CAI) announce on June 16, 2026?

Caris Life Sciences announced a dual listing of its common stock on NYSE Texas. According to Caris, this complements its existing NASDAQ listing and is intended to expand visibility and investor access, particularly within Texas and the broader U.S. equity markets.

When will Caris Life Sciences stock start trading on NYSE Texas and under which ticker symbol?

Caris Life Sciences stock is set to begin trading on NYSE Texas on June 17, 2026. According to Caris, the company will use the same CAI ticker symbol it already uses on NASDAQ for its common shares.

Will Caris Life Sciences keep its NASDAQ listing after adding NYSE Texas (CAI)?

Caris Life Sciences will keep its primary listing and trading of CAI on NASDAQ after the dual listing. According to Caris, NYSE Texas will serve as an additional venue, rather than replacing its existing NASDAQ market presence.

How could the Caris Life Sciences (CAI) dual listing on NYSE Texas affect investors in Texas?

The dual listing is expected to increase visibility and access for Texas-based investors. According to Caris, listing on NYSE Texas aligns with its Texas headquarters and over 450 in-state employees, potentially strengthening local investor engagement and awareness of CAI shares.

What kind of company is Caris Life Sciences (CAI) in AI and precision medicine?

Caris Life Sciences is described as a patient-centric next-generation AI TechBio and precision medicine company. According to Caris, it develops molecular profiling solutions using Whole Genome, Whole Exome and Whole Transcriptome Sequencing, combined with AI and machine learning, to support diagnosis and therapy decisions.

What technologies underpin Caris Life Sciences’ precision medicine platform for CAI investors?

Caris Life Sciences uses Whole Genome, Whole Exome and Whole Transcriptome Sequencing integrated with AI and machine learning. According to Caris, these tools power a large multimodal clinico-genomic database that supports early detection, diagnosis, monitoring, therapy selection and drug development across multiple diseases.